TrovaGene Inc  

(Public, NASDAQ:TROVU)   Watch this stock  
Find more results for TROVU
Sep 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.02 - 20.00
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 85.82M
P/E     -
Div/yield     -
EPS -0.57
Shares 1.67M
Beta     -
Inst. own 204%
Dec 2, 2014
Trovagene Inc at Piper Jaffray Healthcare Conference
Nov 20, 2014
Trovagene Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 19, 2014
Trovagene Inc at Stifel Healthcare Conference
Nov 6, 2014
Q3 2014 Trovagene Inc Earnings Call
Nov 6, 2014
Q3 2014 Trovagene Inc Earnings Release
Oct 8, 2014
Trovagene Inc at BIO Investor Forum
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9397.24% -4555.81%
Operating margin -6888.51% -4123.64%
EBITD margin - -4073.30%
Return on average assets -62.53% -60.85%
Return on average equity -145.43% -104.97%
Employees 21 -
CDP Score - -


United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


TrovaGene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�s urine-based test addresses market needs, such as women�s healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).

Officers and directors

Thomas H. Adams Jr., Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Antonius P. Schuh Ph.D. Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Stephen L. Zaniboni Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Paul R. Billings M.D., Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Gabriele M. Cerrone Director
Age: 41
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 66
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters